| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.13 | 2e-05 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-05 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.18 | 3e-05 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-05 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 3e-05 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.12 | 4e-05 |